SCHEMBL14329949

SCHEMBL14329949

CSc1sc2ncccc2c1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.42
HSP90AA1 P07900 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
LIMK1 P53667 3/20 0.42
LMNA P02545 2/20 0.38
TSHR P16473 1/20 0.38
RAB9A P51151 1/20 0.38
IKBKB O14920 1/20 0.38
CHUK O15111 1/20 0.38
CDC7 O00311 1/20 0.38
CLK1 P49759 1/20 0.38
DBF4 Q9UBU7 1/20 0.38
TP53 P04637 1/20 0.37
POLB P06746 1/20 0.36
KMT2A Q03164 1/20 0.36
ABCG2 Q9UNQ0 1/20 0.36
HPGD P15428 3/20 0.36
PDK1 Q15118 1/20 0.36
KAT2B Q92831 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3123867 0.81 LIMK1 (0.38) NPC1HSP90AA1L3MBTL1LIMK1LMNA
SCHEMBL30059934 0.77 NPC1 (0.48) NPC1HSP90AA1L3MBTL1LIMK1LMNA
SCHEMBL13029609 0.77 NPC1 (0.48) NPC1HSP90AA1L3MBTL1LIMK1LMNA
SCHEMBL4109263 0.76 IKBKB (0.43) L3MBTL1LIMK1IKBKBCHUKTP53
SCHEMBL4107925 0.74 KDM4E (0.48) NPC1L3MBTL1LMNARAB9ATP53
SCHEMBL24595805 0.71 NPC1 (0.42) NPC1HSP90AA1L3MBTL1LIMK1LMNA
SCHEMBL10238251 0.71 NPC1 (0.42) NPC1HSP90AA1L3MBTL1LIMK1LMNA
SCHEMBL4903332 0.71 LIMK1 (0.50) NPC1HSP90AA1L3MBTL1LIMK1LMNA
SCHEMBL27388336 0.70 LIMK1 (0.44) NPC1HSP90AA1L3MBTL1LIMK1LMNA
SCHEMBL718586 0.70 NPC1 (0.41) NPC1HSP90AA1L3MBTL1LIMK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130150573-A1 THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS UCB PHARMA S.A. (BE) 2013-06-13 US disclosed
US-8394822-B2 Thieno-pyridine derivatives as MEK inhibitors UCB PHARMA, S.A. (BE) 2013-03-12 US disclosed
US-20120329774-A1 THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS UCB PHARMA S.A. (BE) 2012-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329774-A1 THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS MAP3K6, MAPK1, MAP3K20 NPC1 4851/4885HSP90AA1 1952/4885L3MBTL1 2568/4885
US-20130150573-A1 THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS MAP2K2, MAPK1, MAP3K6 NPC1 4877/4885HSP90AA1 3045/4885L3MBTL1 3868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.